Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9868926 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL17264874 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8281878 | 0.97 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8281881 | 0.97 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8281880 | 0.97 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9004334 | 0.79 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL27431188 | 0.79 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL30896282 | 0.79 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL159311 | 0.78 | — | — | |
| SCHEMBL11188215 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-10195181-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170014388-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170014388-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9403810-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | CHRM2 4881/4885CHRM4 4885/4885CHRM5 4884/4885 |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | SIRT1, ADCY5, ASIC1 | CHRM2 818/4885CHRM4 892/4885CHRM5 468/4885 |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | CHRM2 1150/4885CHRM4 919/4885CHRM5 720/4885 |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | CHRM2 898/4885CHRM4 883/4885CHRM5 374/4885 |
| US-11672782-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | CHRM2 898/4885CHRM4 883/4885CHRM5 374/4885 |
| US-20170014388-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | CHRM2 898/4885CHRM4 883/4885CHRM5 374/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | CHRM2 1137/4885CHRM4 1367/4885CHRM5 1006/4885 |
| US-10195181-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | CHRM2 898/4885CHRM4 883/4885CHRM5 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.